MiNK Therapeutics, Inc.
INKTAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Jul 15, 2025 | H.C. Wainwright | Emily Bodnar | $35.00(+22%) | $28.75 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| B. Riley Securities | maintain | Buy | Oct 21, 2026 |
| HC Wainwright & Co. | maintain | Buy | May 18, 2026 |
| HC Wainwright & Co. | maintain | Buy | Apr 1, 2026 |
| HC Wainwright & Co. | upgrade | Neutral →Buy | Aug 15, 2025 |
| HC Wainwright & Co. | downgrade | Buy →Neutral | Jul 15, 2025 |
| William Blair | downgrade | Outperform →Market Perform | Jul 14, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 18, 2025 |
| HC Wainwright & Co. | maintain | Buy | Feb 25, 2025 |
| Baird | maintain | Outperform | Nov 15, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 15, 2024 |
| HC Wainwright & Co. | maintain | Buy | Oct 9, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 13, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 14, 2024 |
| HC Wainwright & Co. | maintain | Buy | Mar 21, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 10, 2023 |
| HC Wainwright & Co. | maintain | Buy | May 12, 2023 |
| HC Wainwright & Co. | maintain | Buy | Apr 19, 2023 |
| HC Wainwright & Co. | maintain | Buy | Mar 22, 2023 |
| Evercore ISI Group | maintain | Outperform | Mar 22, 2023 |
| HC Wainwright & Co. | maintain | Buy | Aug 10, 2022 |
| B. Riley Securities | maintain | Buy | Jan 24, 2022 |
| Baird | maintain | Outperform | Nov 9, 2021 |
| William Blair | maintain | Outperform | Nov 9, 2021 |
| Evercore ISI Group | maintain | Outperform | Nov 9, 2021 |
Earnings History
Next report: Nov 11, 2026 · EPS est. $-0.66| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 13, 2026 | $-0.62 | $-0.60 | — | — |
| May 15, 2026 | $-0.57 | $-0.77 | — | — |
| Mar 17, 2026 | $-0.52 | $-0.68 | — | — |
| Nov 14, 2025 | $-0.65 | $-0.86 | — | — |
| Aug 14, 2025 | $-1.06 | $-0.55 | — | — |
| May 15, 2025 | $-0.70 | $-0.61 | — | — |
| Mar 18, 2025 | $-0.62 | $-0.50 | — | — |
| Nov 14, 2024 | $-0.50 | $-0.80 | — | — |
News
NEW YORK, Nov. 06, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies, today announced preclinical findings from two studies presented at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Phoenix, Arizona. The studies address two distinct mechanisms by which tumors resist treatment: immune-suppressive metastatic environments that limit checkpo…
Webcast to highlight advancement of the randomized Phase 2 trial of agenT-797 in acute lung injury, the ARPA-H collaboration to advance deployable cell therapeutics, and new data released at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting Webcast to highlight advancement of the randomized Phase 2 trial of agenT-797 in acute lung injury, the ARPA-H collaboration to advance deployable cell therapeutics, and new data released at the Society for Immunotherapy of Cancer (SITC) 2026…
NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases and cancer, today announced two poster presentations at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting. The presentations address two distinct areas of cancer research: tumor-cell killing in checkpoint inhibitor–resi…
Clinical-stage agenT-797 iNKT platform selected as therapeutic cell platform for ARPA-H BoSS program aimed at taking living medicines from cryogenic storage toward room temperature
MiNK Therapeutics, Inc. (INKT) Q2 2026 Earnings Call Transcript
MiNK Therapeutics NASDAQ: INKT said it initiated dosing in a randomized Phase II trial of its allogeneic invariant natural killer T-cell therapy, agenT-797, for patients with acute lung injury and acute respiratory distress syndrome, or ARDS, during the second quarter of 2026.
NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering off-the-shelf allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune disorders, today reported financial results for the second quarter ended June 30, 2026, and provided an update on the clinical advancement of its lead candidate, agenT-797.